Abstract
Background
Atherothrombosis, a generalized and progressive process, is currently a major healthcare problem in Mexico.
Methods
The worldwide Reduction of Atherothrombosis for Continued Health (REACH) registry aimed to evaluate risk factors for atherosclerosis, long‐term cardiovascular (CV) event rates, and current management of either patients with established symptomatic atherosclerotic disease or asymptomatic subjects with multiple risk factors for atherothrombotic disease. One‐year follow‐up of the global REACH database was available for 64 977 outpatients. This report includes the Mexican subregistry wherein 62 internists, cardiologists, and neurologists evaluated baseline patient characteristics, risk factors, medications, and CV event rates as primary outcomes at 1‐year follow‐up.
Results
Complete 1‐year follow‐up data were available for 837 Mexicans. We observed a high prevalence of diabetes (47.1%), hypertension (74.7%), and hypercholesterolemia (57.8%). Antiplatelet, antihypertensive and/or glucose‐lowering agents, and lipid‐lowering drugs were used in 87.6%, 84.1%, and 61% of patients, respectively. The all‐cause mortality rate was 3.3%. The composite outcome CV death/myocardial infarction/stroke/hospitalization for atherothrombotic events was higher in the symptomatic group (14.6%) than in asymptomatic subjects with multiple risk factors (5.1%; P = 0.01), similar to Latin American results of the global REACH report. The highest CV event rate occurred among symptomatic atherothrombotic patients with 3 vascular disease locations (30.2%), followed by those with 2 (21.9%) and 1 location (13.4%; P = 0.0006).
Conclusions
Prevalence of risk factors and CV event rates including hospitalization in Mexican atherothrombotic patients was high despite the current medication use, which suggests it is necessary to have more aggressive risk‐factor management. Copyright © 2010 Wiley Periodicals, Inc.
Full Text
The Full Text of this article is available as a PDF (559.3 KB).
REFERENCES
- 1. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747–1757. [DOI] [PubMed] [Google Scholar]
- 2. Rosamond W, Flegal K, Furie K, et al; for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25–e146. [DOI] [PubMed] [Google Scholar]
- 3. Meaney E, Lara‐Esqueda A, Ceballos‐Reyes GM, et al. Cardiovascular risk factors in the urban Mexican population: the FRIMEX study. Public Health 2007; 121: 378–384. [DOI] [PubMed] [Google Scholar]
- 4. Mitchell BD, González Villalpando C, Arredondo Pérez B, et al. Myocardial infarction and cardiovascular risk factors in Mexico City and San Antonio, Texas. Arterioscler Thromb Vasc Biol 1995; 15: 721–725. [DOI] [PubMed] [Google Scholar]
- 5. Droste DW, Ringelstein EB. Evaluation of progression and spread of atherothrombosis. Cerebrovasc Dis 2002; 13(suppl 1): 7–11. [DOI] [PubMed] [Google Scholar]
- 6. Coccheri S; for CAPRIE Investigators. Distribution of symptomatic atherothrombosis and influence of the atherosclerotic disease burden on risk of secondary ischemic events: results from CAPRIE. Eur Heart J 1998; 19: 1268. [Google Scholar]
- 7. Bhatt DL, Topol EJ. Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease. Med Clin North Am 2000; 84: 163–179. [DOI] [PubMed] [Google Scholar]
- 8. Bhatt DL, Steg PG, Ohman EM, et al; for the REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180–189. [DOI] [PubMed] [Google Scholar]
- 9. Steg G, Bhatt DL, Wilson PWF, et al; for the REACH Registry Investigators. One‐year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007; 297: 1197–1206. [DOI] [PubMed] [Google Scholar]
- 10. Ohman EM, Bhatt DL, Steg G, et al; for the REACH Registry Investigators. The Reduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events—study design. Am Heart J 2006; 151: 786e1–786e10. [DOI] [PubMed] [Google Scholar]
- 11. Chang IM, Gelman R, Pagano M. Corrected group prognostic curves and summary statistics. J Chron Dis 1982; 35: 669–674. [DOI] [PubMed] [Google Scholar]
- 12.Instituto Nacional de Estadística y Geografia (INEGI), México. Statistics on general mortality [in Spanish]. http://www.inegi.org.mx. Accessed February 15, 2010.
- 13. Fowkes FG, Low LP, Tuta S, et al; for AGATHA Investigators. Ankle‐brachial index and extent of atherothrombosis in 8891 patients with or at risk of vascular disease: results of the international AGATHA study. Eur Heart J 2006; 27: 1861–1867. [DOI] [PubMed] [Google Scholar]
- 14. Hirsch AT, Criqui MH, Treat‐Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317–1324. [DOI] [PubMed] [Google Scholar]
- 15. Schargrodsky H, Hernández‐Hernández R, Champagne BM, et al; for CARMELA Study Investigators. CARMELA: assessment of cardiovascular risk in seven Latin American cities. Am J Med 2008; 121: 58–65. [DOI] [PubMed] [Google Scholar]
- 16. De Backer G, Ambrosioni E, Borch‐Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601–1610. [DOI] [PubMed] [Google Scholar]
- 17. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006; 47: 2130–2139. [DOI] [PubMed] [Google Scholar]
- 18. Sanz J, Moreno PR, Fuster V. The year in atherothrombosis. J Am Coll Cardiol 2008; 51: 944–955. [DOI] [PubMed] [Google Scholar]